Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Popular drugs like Ozemic and Monjauro aid in managing diabetes by lowering blood sugar levels. They have surged in ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to focus on GLP-1 products.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Northstrive Biosciences announced an update for its obesity treatment candidates, EL-22 and EL-32, both aimed at optimizing fat loss while ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.